Beam Therapeutics Inc. (BEAM)

Subscribers to  Chart of the Week  received this commentary on Sunday, March 30.

Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have...

Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.

On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 anti...

BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago.

The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...